FDA's final rule mandates warning for nonoxynol 9 OTC contraceptives
The FDA has issued a final rule that requires manufacturers of OTC stand-alone vaginal contraceptive and spermicidal products containing the chemical ingredient nonoxynol 9 (N9) to include a warning that the chemical N9 does not provide protection against infection from HIV or other sexually transmitted diseases (STDs). Stand-alone spermicides include gels, foams, films, or inserts containing N9 that are used by themselves for contraception. In addition, FDA is requiring that the labels warn consumers that the chemical N9 in stand-alone vaginal contraceptives and spermicides can irritate the vagina and rectum, which may increase the risk of contracting HIV/AIDs from an infected partner. The full text of the final rule is posted atwww.fda.gov/OHRMS/DOCKETS/98fr/80n-0280-nfr0003.pdf.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.